Nutra Pharma Files Provisional Patent for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

CORAL SPRINGS, Fla., April 10, 2018 -- via OTC PR WIRE-- Nutra Pharma Corporation (OTC:NPHC), a biotechnology company marketing Nyloxin^® and Pet Pain-Away^™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have filed a new provisional patent to protect their intellectual property surrounding their development of a drug to treat Amyotrophic Lateral Sclerosis (ALS or “Lou Gehrig’s Disease”).

"Our primary drug for the treatment of Multiple Sclerosis is RPI-78M,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “This drug had been used in previous trials for the treatment of ALS with varying results. We now believe that we have discovered the modifications that are necessary to allow RPI-78M to work effectively against ALS progression,” he continued. “We are filing new intellectual property surrounding these findings and will be working with experts in the field to create the new version of the drug. Once the drug is validated, we will move into animal models in ALS that will allow us to pursue broader trials and seek partners to further this research,” he concluded.

Amyotrophic lateral sclerosis (ALS) is a rare neurological disease that mainly involves the nerve cells (neurons) responsible for controlling voluntary muscle movement like; chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. Currently, there is no cure for ALS and no effective treatment to halt, or reverse, the progression of the disease. Most people with ALS die from respiratory failure, usually within 3 to 5 years from when the symptoms first appear. However, about 10 percent of people with ALS survive for 10 or more years. The US Centers for Disease Control and Prevention estimates that 20,000 to 30,000 people have ALS in the United States, with about 5,000 new cases diagnosed every year. It affects people of all races and ethnic backgrounds.

“The company has a demonstrated molecular mechanism of action for RPI-78M relevant to the pathophysiology of ALS,” reported Dale VanderPutten, PhD, Chief Scientific Officer of Nutra Pharma. “Understanding the shortfalls of previous ALS trials, we realized that while RPI-78M was providing better function, it was not inhibiting the progression of the disease,” he continued. “By appreciation that a foundation of ALS progression is oxidative stress, we determined that adding antioxidant capacity targeted directly to the nerves being affected should improve the performance of the drug in ALS patients," Dr. VanderPutten concluded.

ALS is considered to be an “orphan condition” because of the limited number of patients but the condition gained widespread prominence in 2014 when Pete Frates, a former baseball player at Boston College who has been living with ALS since 2012, started the Ice Bucket Challenge. The viral sensation vastly improved awareness of the condition and caused a huge uptick in donations to the ALS Association.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.nyloxin.com
http://www.petpainaway.com 

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The filing of this provisional patent should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact:
Nutra Pharma Corp.
Nina Goldstein
877-895-5647
[email protected]